Viemed Healthcare (VMD) remains a Buy on strong revenue/earnings growth, accretive acquisitions, and cheap valuation. See here for more details.

AUSTIN, Texas--(BUSINESS WIRE)--VMD Sciences, LLC, a pioneering company dedicated to accelerating biomedical innovation for pets, veterinarians, and pet owners, today announces the launch of its ...

A C-17 Globemaster III assigned to the 701st Airlift Squadron, Joint Base Charleston, S.C., taxis out during Exercise Patriot Sands, Homestead Air Reserve Base, Fla., Feb. 23, 2019. (U.S. Air Force ...

Revenue: $71.9 million, representing 24% year-over-year growth and 14% sequential growth. Gross Profit: $41.3 million, with a 57.5% gross margin. Adjusted EBITDA: $16.1 million, up 16% from the prior ...

VIEMED HEALTHCARE ($VMD) posted quarterly earnings results on Monday, March 10th. The company reported earnings of $0.10 per share, missing estimates of $0.11 by $0. ...

The acquisition, completed in partnership with institutional capital, adds to a series of high-performing strategic transactions by the firm across Massachusetts. Over the past two years, VMD has ...

Viemed Healthcare's stock has declined recently, but bullish EPS revisions and strong growth projections make it an attractive buy near its long-term bottom. The company projects significant revenue ...

NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then released ...